塞来昔布在2型糖尿病中的作用及其机制

目的：探讨新型非甾体抗炎药塞来昔布在2型糖尿病中作用及其机制。方法：80例患者随机分为拜唐平＋二甲双胍治疗方案组（A组）、塞来昔布联合拜唐平＋二甲双胍治疗方案组（B组）及20例健康对照组。比较各组治疗前、后血糖、C-反应蛋白（C—Reaction protein，CRP）、核转录因子-κB mRNA水平，肿瘤坏死因子（TNF—α）、白介素-2（IL-2）、白介素-6（IL-6）含量水平的差异；比较各治疗组治疗前与治疗后上述各指标含量的差异。结果：治疗前各治疗组与健康对照组相比较血糖、CRP、血中NF—κB mRNA水平，TNF—α、IL-2、IL-6含量水平的差异均有显著性（P〈0．05）；各治疗组治疗前、后之间CRP、血中NF—κB mRNA水平，TNF—α、IL-2、IL-6含量水平的差异均有显著性（P〈0．05）；治疗后，治疗组1与治疗组2相比较，血糖差异无显著性（P〈0．05）。结论：在2型糖尿病患者中存在明显的炎症反应过程，塞来昔布作为新型非甾体抗炎药，其不仅具有明显的抗炎症反应，且可降低患者的血糖水平。

Celecoxib in type-2 diabetes mellitus: the actions and underlying mechanisms

Objective： To investigate the action and underlying mechanism of Celecoxib, a novel non- steroidal antiinflammatory drug, in type-2 diabetes mellitus （ DM ）. Methods ： Eighty patients with DM were randomized to treatment on Acarbose plus Metformin （Group A） , or Celecoxib, Acarbose plus Metformin （Group B）. Twenty healthy subjects were recruited as controls. The levels of blood glucose,C-reactive protein（CRP）, NF-κB mRNA, TNF-α, IL-2 and IL-6 before and after therapy were compared between and within groups. Results ：Significant differences between treatment group and controls were noted in blood glucose, CRP, NF-κB mRNA, TNF-α, IL-2 and IL-6 （ P 〈 0.05 ）. In each treatment group, There was an increase from baseline in CRP, NF-κB mRNA, TNF-α, IL-2 and IL-6 （ P 〈 0.05 ）. No significant difference in level of blood glucose after treatment was noted between Groups A and B （ P 〈 0.05 ）. Conclusion ： Type 2 diabetes mellitus is obvious associated with systemic inflammation. The novel non-steroidal anti-inflammatory drug Celecoxib is shown to suppress inflammatory reactions and reduce the level of blood glucose. The mechanism underlying these actions may be inhibition of NF-κB activation, which in turn blocks release of inflammatory factors and ultimately leads to lowered incidence of complications in type 2 diabetes mellitus.